Abbie is a partner at Third Rock Ventures, which she joined in 2016 bringing 30 years of experience in R&D and senior leadership roles. She is currently a board member of Goldfinch Bio and former President and CEO of Eleven Biotherapeutics. Previously, Abbie was the president and CEO of Taligen Therapeutics, when Taligen Therapeutics was acquired by Alexion Pharmaceuticals; following the acquisition, she served as Alexion’s Executive Vice President, Translational Medicine. She has served as the Global Head of Biologics of Novartis AG, the Senior Vice President of R&D Strategy and Operations of Millennium Pharmaceuticals (now Takeda) and the Vice President of Protein Technologies of the Wyeth Research facilities. Abbie is a member of the MassBio Board of Directors, a member of the Board of Panoptica and a member of the Scientific Advisory Board for Adimab. She is also a member of the Board of Directors of the nonprofits Unitio and T1D.
Abbie received a B.A. in biology from the University of California, San Diego, and a Ph.D. in molecular biology from the University of Arizona.